News Roundup | FLCCC Alliance Responds to New NIH Stance On Ivermectin

FLCCC Alliance Issues Public Response to New NIH Recommendation on the Use of Ivermectin:
did an episode of Beyond The Roundup, where we discussed how the NIH, AFTER having met with the FLCCC and Dr. Andrew Hill, put out an interim update, that softened their stance on Ivermectin, for the use of Covid-19. The new recommendation from the NIH, changed their stance from against the use of Ivermectin for Covid-19, with the exception of clinical trials, to neither for, nor against the use of the drug against the virus.
https://trialsitenews.com/flccc-alliance-issues-public-response-to-new-nih-recommendation-on-the-use-of-ivermectin/

Growing Momentum for Ivermectin in German Press as Pharmacy Journal Introduces Ivermectin as Possible Treatment for COVID-19:
The Deutsche Apotheker Zeitung (DAZ) represents an independent pharmaceutical journal for science and practice. Appearing weekly, the publication is targeted for pharmacists and other pharmaceutical professional groups. Their website DAZ.online is read by health and pharmacy professionals in Germany interested in health policy and evidence-based pharmacy. Although the topic of Ivermectin hasn’t been broadly discussed in much Western press, on both sides of the Atlantic, that is now appearing to be changing. Since the Front Line COVID-19 Critical Care Alliance (FLCCC) announced their meta-analysis based on Ivermectin studies targeting COVID-19, the topic has been gaining momentum by the day.
https://trialsitenews.com/growing-momentum-for-ivermectin-in-german-press-as-pharmacy-journal-introduces-ivermectin-as-possible-treatment-for-covid-19/

London School of Hygiene Tropical Medicine Launches Major Ivermectin Study in The Gambia Focusing on COVID-19:
The London School of Hygiene Tropical Medicine (LSHTM) has launched a major Ivermectin study West African country of The Gambia. Targeting 1,200 participants, the investigators from the LSHTM’s Medical Research Council (MRC) unit will assess the impact of Ivermectin and many regulatory bodies around the world, on the natural history of SARS-CoV-2 in two cohorts, including 1) those with mild or moderate pneumonia (Cohort 1) and 2) those with severe pneumonia (Cohort 2), via a randomization to non-identical placebo or intervention arm.
https://trialsitenews.com/london-school-of-hygiene-tropical-medicine-launches-major-ivermectin-study-in-the-gambia-focusing-on-covid-19/